Lin Bo, Dong Xu, Wang Qiujiao, Li Wei, Zhu Mingyue, Li Mengsen
Hainan Provincial Key Laboratory of Carcinogenesis and Intervention, Hainan Medical College, Haikou, China.
Institution of Tumor, Hainan Medical College, Haikou, China.
Front Cell Dev Biol. 2021 Apr 8;9:635476. doi: 10.3389/fcell.2021.635476. eCollection 2021.
Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future.
甲胎蛋白（AFP）在刺激肝细胞癌（HCC）的生长、转移和耐药性方面起着关键作用。AFP是肝癌治疗中的一个重要靶分子。应用AFP衍生肽、AFP片段和重组AFP（AFP抑制片段，AIFs）抑制AFP与细胞内蛋白质或其受体的结合，是治疗HCC和其他癌症新策略的基础。此外，AIFs可与药物和递送剂结合用于癌症的靶向治疗。与抗癌药物偶联的AIFs不仅能用这些药物破坏癌细胞，还能激活免疫细胞来杀死癌细胞。此外，AIF介导的药物递送可减轻免疫抑制并增强化疗效果。免疫疗法和靶向化疗的协同作用有望在提高癌症患者的治疗效果中发挥重要作用。AIF介导的药物递送将成为未来癌症靶向治疗的一种可行策略。
